A comparison of cyclosporine A and Nva2-cyclosporine (cyclosporine G) in a rat renal allograft model.
We compared CsG and CsA in the DA-to-Lewis rat renal allograft model. At equivalent oral doses, plasma radioimmunoassay (RIA) CsG levels were higher than CsA (P less than 0.02). Neither drug prevented rejection at doses of 5 mg/kg/day. CsG-treated rats had a higher rejection rate at doses of 7.5 mg/kg/day (P less than 0.05). Both drugs were equally effective in preventing rejection at doses of 10 mg/kg/day. Neither drug was nephrotoxic at the doses used in this study. CsG is a potent immunosuppressant, and thus a potential clinical successor to CsA. Since CsG and CsA provide equivalent immunosuppression at therapeutic doses, CsG's clinical significance will ultimately depend on its nephrotoxicity in man.
Grant
D
D
Zhong
R
R
Stiller
C
C
Wallace
C
C
Keown
P
P
Duff
J
J
D000818:Animals; D016572:Cyclosporine; D003524:Cyclosporins / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew / Q000276:immunology; D014184:Transplantation, Homologous
D003524:Cyclosporins; C045571:cyclosporin G; D016572:Cyclosporine